Our company is engaged in two business areas: the "Drug Discovery Business," which aims to commercialize exosomes as pharmaceuticals, and the "Non-Drug Discovery Business," which sells exosomes as raw materials for non-medical products.
The "Drug Discovery Business" consists of two business models: the "Asset Model," where we conduct clinical trials of our assets, and the "Platform Model," where we license our exosome technology.
Among these, the "Asset Model" is the driver of our medium- to long-term growth. Although research and development investments precede revenue, we aim to increase the value of our assets by obtaining evidence of safety and efficacy in clinical trials targeting diseases with high unmet medical needs. By licensing global rights to pharmaceutical companies, we expect to generate significant revenue.
On the other hand, while the future revenue scale of the "Platform Model" and "Non-Drug Discovery Business" is limited compared to the "Asset Model," they enable us to acquire stable cash flow early with less research and development investment, which is expected to contribute to the improvement of our financial health.
By adjusting the weight of these multiple business models according to our growth stage, we aim to achieve continuous growth over the medium to long term while controlling risks.